相关临床试验
3545
534 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1849
终止
199
5.6%
招募中
645
18.2%
暂停
10
0.3%
撤回
93
2.6%
进行中（未招募）
106
3.0%
Unknown
416
11.7%
已完成
1648
46.5%
Enrolling By Invitation
2
0.1%
尚未招募
426
12.0%
暂无批准数据
- AB Science received formal US patent approval (US12,472,164) for masitinib in treating sickle cell disease, providing intellectual property protection until November 2040. - Preclinical studies demonstrated masitinib's survival benefit in sickle cell disease mouse models, with 100% survival in treated mice compared to 83% mortality in controls within three hours. - The company is developing masitinib for severe forms of sickle cell disease representing approximately 65% of cases, targeting mast cell-mediated complications through a fully funded €9.2 million Phase 2 trial.
- AB Science has received a Notice of Allowance from the US Patent Office for masitinib in treating sickle cell disease, providing intellectual property protection until November 2040. - Masitinib uniquely targets mast cells in sickle cell disease treatment, showing promising preclinical results including complete prevention of vaso-occlusive crises and death in mouse models. - Clinical development is progressing through the SICKMAST program with €9.2 million funding, targeting both acute and chronic complications of sickle cell disease based on biomarker identification.
- A Phase 3 ARCADE trial demonstrates that combining irbesartan with celiprolol reduces severe arterial events by 50% in vascular Ehlers-Danlos syndrome patients over two years. - The study showed significant reduction in both symptomatic and asymptomatic arterial lesions, with patients on irbesartan experiencing fewer events (13) compared to placebo (35). - Irbesartan, an affordable generic medication, demonstrated a favorable safety profile with only minor adjustments needed for blood pressure management in some patients.
